Stocks Comparison
Gilead Sciences vs Halozyme Therapeutics: revenue, profit, margins and growth compared
Gilead Sciences brought in $29.4B of revenue in fiscal 2025, Halozyme Therapeutics $1.4B in fiscal 2025. Revenue changed by +2.4% at Gilead Sciences and +37.6% at Halozyme Therapeutics on the year before, so Halozyme Therapeutics grew faster. Gilead Sciences kept 28.9% of its revenue as net profit, Halozyme Therapeutics 22.7%. Free cash flow was $9.5B at Gilead Sciences and $644.6M at Halozyme Therapeutics.
Side by side, latest fiscal year
| GILD | HALO | |
|---|---|---|
| Fiscal year ended | FY2025 (December 31, 2025) | FY2025 (December 31, 2025) |
| Revenue | $29.4B | $1.4B |
| Revenue growth | +2.4% | +37.6% |
| Net income | $8.5B | $316.9M |
| Net margin | 28.9% | 22.7% |
| Free cash flow | $9.5B | $644.6M |
| Free cash flow margin | 32.1% | 46.2% |
| Earnings per share (diluted) | $6.78 | $2.56 |
| Cash | $7.6B | $133.8M |
| Debt | $24.9B | $2.1B |
| Price to earnings | 22.3 | 44.5 |
| Market value | $187.1B | $12.9B |
| Dividend yield | 2.09% | n/a |
| Rank by revenue in sector | #22 of 523 · Health care | #129 of 523 · Health care |
Over the years
Questions about Gilead Sciences and Halozyme Therapeutics
Which is bigger by revenue, Gilead Sciences or Halozyme Therapeutics?
Gilead Sciences is bigger by revenue: $29.4B in fiscal 2025, against $1.4B for Halozyme Therapeutics in fiscal 2025.
Which keeps more of its revenue as profit, Gilead Sciences or Halozyme Therapeutics?
Gilead Sciences had a net margin of 28.9% in fiscal 2025; Halozyme Therapeutics had 22.7% in fiscal 2025.
Which grew revenue faster, Gilead Sciences or Halozyme Therapeutics?
In their latest fiscal years revenue changed by +2.4% at Gilead Sciences and +37.6% at Halozyme Therapeutics.
Where do these numbers come from?
From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.